A study published online in the Proceedings of the National Academy of Sciences on April 14, 2023, showed that strokes cause numerous changes in gene activity in affected microvessels in the brain, and these changes were potentially targetable with existing or future drugs to alleviate brain injury or improve stroke recovery. Treatments available for stroke are very limited and are mainly focused on the recanalization of the obstructed larger cerebral arteries. However, it is known that strokes affect the cerebral microvasculature too, for which there are no current therapies in the clinic.
Rapidai Inc. received FDA 510(k) clearance for its Rapid NCCT Stroke technology, the latest tool in its portfolio of non-contrast-based solutions for shock and trauma care. The company claims it is the first and only medical device cleared by the agency to detect suspected intracranial hemorrhage (ICH) and large vessel occlusion (LVO) from value-based CT imaging.
Brainomix Ltd. received U.S. FDA clearance for its Brainomix 360 E-aspects tool, a fully automated AI-imaging solution for stroke assessment. Powered by explainable AI, the Brainomix 360 E-aspects tool, which is already CE-marked, assesses non-contrast CT scans to automatically generate a score and measures the volume of ischemic signs. It also features an overlaid heatmap to visually assist clinicians when treating stroke patients.
High levels of bilirubin exacerbated damage to neurons in the brain caused by a stroke by binding to the TRPM2 channel, which helped regulate cell death among other processes. The research, published March 14, 2023, in Neuron, showed that blocking the binding site for bilirubin in a mouse model led to improvements in neurotoxicity suggesting some potential for the development of new stroke therapeutics.
High levels of bilirubin exacerbated damage to neurons in the brain caused by a stroke by binding to the TRPM2 channel, which helped regulate cell death among other processes. The research, led by Shanghai Jiao Tong University School of Medicine and the University of Toronto and published March 14, 2023, in Neuron, showed that blocking the binding site for bilirubin in a mouse model led to improvements in neurotoxicity suggesting some potential for the development of new stroke therapeutics.
Methinks Software SL (dba Methinks.AI), a digital health company, is working on the U.S. FDA submission for its artificial intelligence (AI)-based stroke triage software, which will aid in the detection of acute stroke, after recently receiving CE mark certification.
Microglial cells (MGs) are resident immune cells in the brain, which play a key role in the acute response and chronic recovery to stroke. Investigators at the University of Texas Health Science Center Houston aimed to evaluate MG transcriptomic response to stroke in mouse brain.
Researchers from Basking Biosciences Inc. presented preclinical data for BB-031, a novel RNA aptamer that binds and inhibits Von Willebrand Factor (VWF). BB-031 (0.5, 1.0 and 5.0 mg/kg) or placebo were administered to a canine model of large vessel occlusion (LVO) stroke at 6 hours post-LVO with an autologous clot.
Scientists from the National Institutes of Health and affiliated organizations established a novel mouse model of intraventricular extension of hemorrhage (IVH) for the purpose of measuring motor and cognitive function in acute and chronic stages of intracerebral hemorrhage, which is the most severe stroke subtype.